1.Prevalence of prostate cancer following an initial negative MRI-fusion biopsy of the prostate from 2018-2022: A single-center retrospective descriptive cohort
Jose Leuel A. Ongkeko ; Mark C. Cellona
Philippine Journal of Urology 2025;35(1):9-12
OBJECTIVES
To determine the incidence of prostate cancer on follow up after an initial negative MRI- fusion biopsy of the prostate, and to determine the change in PSA and MRI results on follow-up.
METHODSMRI-fusion prostate biopsy registry from 2018 to 2022 was obtained then histopathology, MRI results, and PSA results were obtained. Repeat PSA and MRI results at extracted at 3 years. PSA mean, range, and change were then determined. MRI results were extracted to determine progression, regression, or persistence.
RESULTSA total of 670 prostate biopsies were done in the study period, of which 70 were included. PSA on biopsy 9.93 (3.35 – 55.0) with corresponding PIRADS lesions 3, 4, and 5 (n=55, n=19, and n=6). No patient was subsequently diagnosed with prostate cancer on follow-up. PSA mean 7.03, 6.44, 5.27, and 6.07 at 3years interval from biopsy. Repeat prostate MRI showed persistence in 1 and regression in 6 patients.
CONCLUSIONAfter a negative MRI-fusion biopsy of the prostate no patient developed prostate cancer with a general decrease in trend in PSA and MRI on follow-up. These patients may have longer interval follow-up periods given the clinical scenario but would be best to test this method in prospective trials first.
Human ; Prostate Cancer ; Prostatic Neoplasms
2.Regulation of testosterone synthesis by circadian clock genes and its research progress in male diseases.
Gang NING ; Bo-Nan LI ; Hui WU ; Ruo-Bing SHI ; A-Jian PENG ; Hao-Yu WANG ; Xing ZHOU
Asian Journal of Andrology 2025;27(5):564-573
The circadian clock is an important internal time regulatory system for a range of physiological and behavioral rhythms within living organisms. Testosterone, as one of the most critical sex hormones, is essential for the development of the reproductive system, maintenance of reproductive function, and the overall health of males. The secretion of testosterone in mammals is characterized by distinct circadian rhythms and is closely associated with the regulation of circadian clock genes. Here we review the central and peripheral regulatory mechanisms underlying the influence of circadian clock genes upon testosterone synthesis. We also examined the specific effects of these genes on the occurrence, development, and treatment of common male diseases, including late-onset hypogonadism, erectile dysfunction, male infertility, and prostate cancer.
Testosterone/metabolism*
;
Humans
;
Male
;
Circadian Clocks/genetics*
;
Circadian Rhythm Signaling Peptides and Proteins/metabolism*
;
Circadian Rhythm/physiology*
;
Hypogonadism/metabolism*
;
Erectile Dysfunction/metabolism*
;
Infertility, Male/metabolism*
;
Prostatic Neoplasms/metabolism*
;
Men's Health
3.Sexual activity in men undergoing ADT for localized prostate cancer: a narrative literature review.
Laeticia CREIDY ; Daniel TAUSSKY ; Frederic POULIOT ; Fred SAAD ; Fabian FALKENBACH
Asian Journal of Andrology 2025;27(5):581-585
Androgen deprivation therapy (ADT) can negatively affect sexual function, and only a minority of patients report sexual activity. We reviewed the existing literature regarding the proportion of men who remained sexually active during and after ADT. The PubMed database was searched for studies published over the past 20 years. We selected and reviewed randomized clinical trials that provided sexual function data at baseline and during and after ADT. The primary outcome measure was the sexual function. Studies assessed sexual function using quality of life patient-reported outcome measures, which included sexual potency/activity evaluation. Information from 2947 patients was analyzed in this review. The median age of patients was 70 years. At baseline, a median of 49.9% (95% confidence interval [CI]: 49.1%-50.7%) of the patients reported being sexually active. At 6 months, 12 months, and 2 years or later of ADT treatment, a median of 10.3% (95% CI: 10.2%-10.5%), 8.9% (95% CI: 8.6%-9.2%), and 8.3% (95% CI: 8.2%-8.5%) of the patients reported being sexually active, respectively. Considering that half of the patients were sexually active at baseline, it seems probable that more than 10% of the patients who were sexually active before starting ADT remained sexually active when undergoing ADT. In conclusion, despite the common belief that ADT eliminates sexual activity, this analysis found that approximately 1 in 10 men are sexually active when on ADT, and this proportion is likely increased in men who are sexually active before starting ADT. Attention to sexual activity should not be dismissed in men on ADT.
Humans
;
Male
;
Prostatic Neoplasms/drug therapy*
;
Androgen Antagonists/therapeutic use*
;
Sexual Behavior/drug effects*
;
Quality of Life
;
Aged
4.A propensity score-matched analysis on biopsy methods: enhanced detection rates of prostate cancer with combined cognitive fusion-targeted biopsy.
Bi-Ran YE ; Hui WANG ; Yong-Qing ZHANG ; Guo-Wen LIN ; Hua XU ; Zhe HONG ; Bo DAI ; Fang-Ning WAN
Asian Journal of Andrology 2025;27(4):488-494
The choice of biopsy method is critical in diagnosing prostate cancer (PCa). This retrospective cohort study compared systematic biopsy (SB) or cognitive fusion-targeted biopsy combined with SB (CB) in detecting PCa and clinically significant prostate cancer (csPCa). Data from 2572 men who underwent either SB or CB in Fudan University Shanghai Cancer Center (Shanghai, China) between January 2019 and December 2023 were analyzed. Propensity score matching (PSM) was used to balance baseline characteristics, and detection rates were compared before and after PSM. Subgroup analyses based on prostate-specific antigen (PSA) levels and Prostate Imaging-Reporting and Data System (PI-RADS) scores were performed. Primary and secondary outcomes were the detection rates of PCa and csPCa, respectively. Of 2572 men, 1778 were included in the PSM analysis. Before PSM, CB had higher detection rates for both PCa (62.9% vs 52.4%, odds ratio [OR]: 1.54, P < 0.001) and csPCa (54.9% vs 43.3%, OR: 1.60, P < 0.001) compared to SB. After PSM, CB remained superior in detecting PCa (63.1% vs 47.9%, OR: 1.86, P < 0.001) and csPCa (55.0% vs 38.2%, OR: 1.98, P < 0.001). In patients with PSA 4-12 ng ml -1 (>4 ng ml -1 and ≤12 ng ml -1 , which is also applicable to the following text), CB detected more PCa (59.8% vs 40.7%, OR: 2.17, P < 0.001) and csPCa (48.1% vs 27.7%, OR: 2.42, P < 0.001). CB also showed superior csPCa detection in those with PI-RADS 3 lesions (32.1% vs 18.0%, OR: 2.15, P = 0.038). Overall, CB significantly improves PCa and csPCa detection, especially in patients with PSA 4-12 ng ml -1 or PI-RADS 3 lesions.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Propensity Score
;
Retrospective Studies
;
Middle Aged
;
Aged
;
Image-Guided Biopsy/methods*
;
Prostate-Specific Antigen/blood*
;
Prostate/diagnostic imaging*
5.Sexual function recovery following open and robotic radical prostatectomy: results of an academic penile rehabilitation program.
Michele Di NAUTA ; Ugo Giovanni FALAGARIO ; Anna RICAPITO ; Matteo RUBINO ; Pasquale ANNESE ; Gian Maria BUSETTO ; Luigi CORMIO ; Giuseppe CARRIERI ; Carlo BETTOCCHI
Asian Journal of Andrology 2025;27(6):680-685
Despite surgical advancements, erectile dysfunction (ED) is a common consequence of radical prostatectomy (RP). This study aimed to evaluate the impact of early penile rehabilitation within a dedicated penile rehabilitation program on assisted and unassisted erectile function (EF) recovery. All patients who underwent RP and at least 1 year follow-up at penile rehabilitation program in the Department of Urology, OORR Policlinico Riuniti (Foggia, Italy) were included. Treatment involved phosphodiesterase type 5 inhibitors (PDE5Is; tadalafil 20 mg, 1 tablet every other day), intracavernous injections (Caverject 5 µg, 1 vial per week), and daily use of vacuum erection devices (VEDs). Primary end point was EF recovery defined as International Index of Erectile Function-5 (IIEF-5) ≥21 with or without rehabilitation aids. IIEF-5 and prescribed treatments were prospectively collected at 3 months, 6 months, 9 months, 12 months, and 24 months. Among 570 eligible patients, 397 (69.6%) underwent rehabilitation. Patients who undergoing andro-rehabilitation were younger (65 months vs 70 months; P < 0.0001), had lower prostate-specific antigen (PSA) levels (5.9 ng ml -1 vs 6.2 ng ml -1 ; P = 0.04), and lower grade tumors ( P = 0.001) compared to the patients who did not undergo sexual rehabilitation after radical prostatectomy. Two-year EF recovery rates in patients undergoing andro-rehabilitation ranged from 75% (preoperative IIEF-5 >16) to 45% (preoperative IIEF-5 <16) with rehabilitation aids. Combination treatments (PDE5I+VEDs with or without intracavernous injections) showed the highest rates of EF recovery (up to 80% at 2 years). EF recovery without rehabilitation aids was significantly higher for patients with IIEF-5 >21 (IIEF-5 >21 [36%] vs IIEF-5 of 17-21 [18%]; P = 0.01). Subanalysis indicated a moderate benefit of rehabilitation in patients with preoperative IIEF-5 <16 who underwent bilateral nerve-sparing RP. Participation in intensive penile rehabilitation programs improves EF recovery in patients undergoing RP. Preserving the neurovascular bundles may be beneficial for patients with preoperative ED.
Humans
;
Male
;
Prostatectomy/rehabilitation*
;
Middle Aged
;
Erectile Dysfunction/drug therapy*
;
Aged
;
Recovery of Function
;
Robotic Surgical Procedures/adverse effects*
;
Phosphodiesterase 5 Inhibitors/therapeutic use*
;
Penile Erection
;
Tadalafil/therapeutic use*
;
Prostatic Neoplasms/surgery*
;
Treatment Outcome
6.Recent advances in antibody-drug conjugates for metastatic castration-resistant prostate cancer.
Jiacheng XU ; Yutao MA ; Pengcheng HU ; Jiatao YAO ; Haichao CHEN ; Qi MA
Journal of Zhejiang University. Medical sciences 2025;54(5):685-693
Patients with metastatic castration-resistant prostate cancer (mCRPC) face poor prognoses due to tumor heterogeneity and drug resistance. Antibody-drug conjugates (ADCs) have been under development for over two decades for mCRPC treatment. Several clinical trials have demonstrated promising antitumor activity and acceptable safety profiles for ADCs in this setting. Among prostate-specific membrane antigen (PSMA)-targeted ADCs, ARX517 demonstrates superior safety and more significant prostate-specific antigen (PSA) reductions compared to earlier agents such as MLN2704, PSMA-ADC, and MEDI3726. ADCs targeting B7-H3, such as MGC018 and DB-1311, have also shown antitumor activity. ADCs targeting other antigens, including six-transmembrane epithelial antigen of the prostate (STEAP)1 (DSTP3086S), trophoblast cell surface antigen (TROP)2 (sacituzumab govitecan), and solute carrier (SLC) 44A4 (ASG-5ME), have shown preliminary antitumor activity in early trials but face challenges with insufficient efficacy or toxicity. Tisotumab vedotin (targeting tissue factor) has shown no significant therapeutic response in mCRPC. Meanwhile, disitamab vedotin (HER2-targeted), ABBV-969 and DXC008 (both dual PSMA/STEAP1-targeted) are currently under evaluation. Notably, an international multicenter phase Ⅲ clinical trial (NCT06925737) for mCRPC has been initiated in May 2025 for evaluating B7-H3-targeted ADC ifinatamab deruxtecan. This review summarizes recent advances in ADCs targeting key antigens in mCRPC (including PSMA, B7-H3, STEAP1, TROP2, SLC44A4, and others) and explores combination strategies, offering insights to inform the clinical management of mCRPC.
Humans
;
Prostatic Neoplasms, Castration-Resistant/pathology*
;
Male
;
Immunoconjugates/therapeutic use*
;
Glutamate Carboxypeptidase II/immunology*
;
Antibodies, Monoclonal, Humanized/therapeutic use*
;
B7 Antigens/immunology*
;
Neoplasm Metastasis
;
Prostate-Specific Antigen
;
Antigens, Neoplasm/immunology*
;
Antigens, Surface
;
Camptothecin/analogs & derivatives*
;
Oxidoreductases
7.PI-RADS v2.1 score combined with PSA density for diagnosis of clinically significant prostate cancer in the PSA grey zone by MRI-TRUS cognitivefusion-guided transperineal targeted prostate biopsy.
Yue LI ; Shan ZHOU ; Jing CHEN ; Fei MAO ; Xiao-Bing NIU ; Li SUN ; Ming XU ; Jin-Tao LIU
National Journal of Andrology 2025;31(1):50-54
OBJECTIVE:
To assess the value of the Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) score combined with PSA density (PSAD) in the diagnosis of clinically significant prostate cancer (CSPCa) in the PSA grey zone by MRI-TRUS cognitive fusion-guided transperineal targeted prostate biopsy.
METHODS:
This retrospective study included 327 male patients with total PSA (tPSA) levels of 4-10 μg/L undergoing MRI-TRUS cognitive fusion-guided transperineal targeted prostate biopsy in our hospital between January 2021 and December 2023. According to the pathological results, we divided the patients into a CSPCa (n = 44) and a non-CSPCa group (n = 283), collected their clinical and imaging data, and subjected them to statistical analysis.
RESULTS:
The age, tPSA level, PSAD and PI-RADS score were significantly higher, while the free PSA (fPSA) level, f/tPSA ratio and prostate volume remarkably lower in the CSPCa than in the non-CSPCa group (P<0.05). The areas under the curve (AUCs) of PSAD, PI-RADS score and their combination were 0.772, 0.730 and 0.801, with sensitivities of 63.63%, 70.45% and 72.73%, and specificities of 84.10%, 75.62% and 83.75%, respectively (P<0.01). With PSAD 0.2 μg/(ml·cm3) as the best cut-off value and based on the PI-RADS scores, the patients were divided into two groups for analysis. In the patients with PI-RADS scores 2 and 5, the AUCs were 0.534 and 0.643, with sensitivities of 16.67% and 63.64%, and specificities of 85.14% and 64.29%, with no statistically significant differences (P= 0.784, P= 0.228), and in those with PI-RADS scores 3 and 4, the AUCs were 0.794 and 0.843, with sensitivities of 57.14% and 80.00%, and specificities of 87.14% and 81.82%, with statistically significant differences (P= 0.009, P<0.001).
CONCLUSION
PI-RADS v2.1 score combined with PSAD can effectively improve the diagnostic efficiency of CSPCa in the PSA grey zone by MRI-TRUS cognitive fusion-guided transperineal targeted prostate biopsy and serve as a guide for selection of prostate biopsy.
Humans
;
Male
;
Prostatic Neoplasms/diagnostic imaging*
;
Retrospective Studies
;
Prostate-Specific Antigen
;
Magnetic Resonance Imaging
;
Image-Guided Biopsy
;
Prostate/pathology*
;
Aged
;
Middle Aged
8.Irreversible electroporation for the treatment of prostate cancer: An update.
Xiao-Xu JIN ; Xiao-Dong ZHAO ; Song XU
National Journal of Andrology 2025;31(1):76-80
Prostate cancer (PCa) is globally the most prevalent malignancy in the male genitourinary system, with a continuously ascending incidence in China. For the treatment of localized PCa, radical prostatectomy and radiotherapy have demonstrated effective suppression of the tumor, but with obvious complications that markedly compromise the life quality of the patients. Focal therapy, by targeting the principal tumor foci, can largely reduce the incidence of complications. In this context, irreversible electroporation represents an emerging modality of focal treatment capable of ablating the tumor as thoroughly as possible while sparing such critical structures as the urethra, rectum and neurovascular bundles from thermal damage, and thus offers a promising option for the management of localized PCa. This article presents an overview of the latest advances in the studies of irreversible electroporation.
Humans
;
Male
;
Prostatic Neoplasms/therapy*
;
Electroporation/methods*
9.Relationship between sterol carrier protein 2 gene and prostate cancer: Based on single-cell RNA sequencing combined with Mendelian randomization.
Jia-Xin NING ; Shu-Hang LUO ; Hao-Ran WANG ; Hui-Min HOU ; Ming LIU
National Journal of Andrology 2025;31(5):403-411
Objective: To investigate the relationship between the lipid metabolism-related gene sterol carrier protein 2(SCP2) and prostate cancer (PCa) from a multi-omics perspective using single-cell transcriptomes combined with Mendelian randomization. Methods: Single-cell transcriptome data of benign and malignant prostate tissues were obtained from GSE120716, GSE157703 and GSE141445 datasets, respectively. Integration, quality control and annotation were performed on the data to categorize the epithelial cells into high and low SCP2 expression groups, followed by further differential and trajectory analyses. Single nucleotide polymorphism (SNP) data for SCP2 expression quantitative trait loci (eQTL) were subsequently downloaded from Genotype-Tissue Expression (GTEx) and investigated from the PCa Society Cancer-Related Genomic Alteration Panel for the Investigation of Cancer-Related Alterations (PRACTICAL) to obtain PCa outcome data for Mendelian randomization analysis to validate the causal relationship between SCP2 and PCa. Results: High SCP2-expressing epithelial cells had higher energy metabolism and proliferation capacity with low immunotherapy response and metastatic tendency. Trajectory analysis showed that epithelial cells with high SCP2 expression may have a higher degree of malignancy, and SCP2 may be a key marker gene for differentiation of malignant epithelial cells in the prostate. Further Mendelian randomization results showed a significant causal relationship between SCP2 and PCa development (OR=1.045, 95% CI: 1.010 -1.083, P=0.011). Conclusion: By combining single-cell transcriptome and Mendelian randomization, the role of the lipid metabolism-related gene SCP2 in PCa development has been confirmed, and new targets and therapeutic directions for PCa treatment have been provided.
Humans
;
Prostatic Neoplasms/genetics*
;
Male
;
Mendelian Randomization Analysis
;
Polymorphism, Single Nucleotide
;
Quantitative Trait Loci
;
Single-Cell Analysis
;
Sequence Analysis, RNA
;
Carrier Proteins/genetics*
;
Transcriptome
;
Lipid Metabolism
10.Clinical prediction model for patients with early-onset prostate cancer without surgical treatment: Based on the SEER Database.
Han-Dong LIU ; Han-Yu JIA ; Jing WANG ; Li-Ping ZHANG
National Journal of Andrology 2025;31(5):412-420
OBJECTIVE:
The aim of this study is to investigate the risk factors of prognosis in patients with early-onset prostate cancer treated without surgery. A nomogram will be constructed and validated to predict overall survival (OS) of patients with early-onset prostate cancer treated without surgery.
METHODS:
The clinical data was obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database on prostate cancer patients aged 18-55 years who were treated without surgery between 2010 and 2015. The clinical data set was divided into training set and validation set according to 7∶3 ratio, including age, race, marital status, Gleason score, prostate specific antigen (PSA) and other 8 factors. And significant variables were screened by univariate Cox regression analysis. Multivariate Cox regression analysis was used to identify the influence factors. Stepwise regression method was used to select the most influential factors on the total OS, and R software was used to build a nomogram model. The accuracy and prediction ability of the model were verified by drawing receiver operating characteristic (ROC) and Calibration Plot. The clinical benefit of the model was evaluated by decision curve analysis (DCA).
RESULTS:
A total of 8 212 patients who met the criteria were randomly assigned to the training set (n=5 752) or validation set (n=2 460), with no statistical difference between the two groups (all P>0.05). Six factors were identified through univariate and multivariate Cox regression analysis including marital status, N stage, M stage, radiotherapy, PSA and Gleason score, which were most closely associated with the OS of prostate cancer patients, and a column graph model was constructed based on these factors. The Consistency index (C-index) of the model in the training set and the verification set were 0.802 and 0.794, respectively. And the apparent diffusion coefficient (AUC) was 0.851, 0.855 and 0.855 for training sets 1, 3 and 5 years, and 0.694, 0.860 and 0.832 for verification sets 1, 3 and 5 years. The calibration chart showed a good agreement between the predicted and actual values of the model. In the analysis of decision curve, the model showed good clinical application value.
CONCLUSION
The prediction model based on marital status, radiotherapy, M stage, N stage, PSA and Gleason score for early-onset prostate cancer patients without surgical treatment has certain reference value which is expected to become an effective tool for clinicians to treat in future prospective studies on large and multi-center samples.
Humans
;
Male
;
Prostatic Neoplasms/diagnosis*
;
Middle Aged
;
Nomograms
;
SEER Program
;
Prognosis
;
Adult
;
Prostate-Specific Antigen
;
Risk Factors
;
Proportional Hazards Models
;
Neoplasm Grading
;
ROC Curve


Result Analysis
Print
Save
E-mail